Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus
A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus
2 other identifiers
interventional
400
6 countries
56
Brief Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Nov 2008
56 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 13, 2008
CompletedFirst Posted
Study publicly available on registry
October 15, 2008
CompletedStudy Start
First participant enrolled
November 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedJuly 1, 2010
June 1, 2010
1.6 years
October 13, 2008
June 30, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
TBF-12 (Tinnitus-Beeinträchtigungs-Fragebogen-12 "Tinnitus Handycap Inventory-12") total score change from baseline to end of treatment
Screening, Baseline, week 5, 13, 17
Secondary Outcomes (2)
TBF-12 factorial scores, individual respond rate, Tinnitus Rating Scale, Sleep Questionnaire, Qualitiy Of Life, population pharmacokinetics, optional pharmacogenetics
29 weeks
safety parameters
29 weeks
Study Arms (2)
1
EXPERIMENTALDrug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
2
PLACEBO COMPARATORDrug: Placebo Double-blind treatment period of 17 weeks placebo
Interventions
Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
Eligibility Criteria
You may qualify if:
- patients aged 18 to 75 years with a clinical diagnosis of first onset, persistent (i.e. tinnitus sghould never be absent for \>24 hours in a row), subjective, uni-or bilateral tinntius present for at least 3 months but not more than 12 months.
You may not qualify if:
- Clinical diagnosis of intermittent or pulsatile tinnitus
- Patients who have tinnitus as a concomitant symptom of an otological/neurological disease(such as otitis media, Meniére´s disease, otosclerosis, etc.)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (56)
AZ Sint Lucas, ENT department
Assebroek-Brugge, 8310, Belgium
University Hospital Brussels, ENT department
Brussels, 1090, Belgium
Clinique Universitaire Saint-Luc
Brussels, 1200, Belgium
Dr. Henri HABERMAN
Brussels, 1200, Belgium
AZ Sint Lucas, ENT department
Ghent, 9000, Belgium
Centre hospitalier de jolimont
La Louvière, 7100, Belgium
University Hospital Leuven, ENT Department
Leuven, 3000, Belgium
CHU Liege Service ORL
Liège, 4000, Belgium
Medico
Chodov, Prague, Czechia
Prof. MUDr. Ivo Šlapák, CSc
Brno, 60200, Czechia
Teaching University Hospital, ORL klinika
Brno, 65691, Czechia
Nemocnice Havlíčkův Brod
Havlíčkův Brod, 58022, Czechia
ORL - Otorynolaryngologické oddělení
Jihlava, 58633, Czechia
ORL oddělení, Karlovarská krajská nemocncie a.s.
Karlovy Vary, 36066, Czechia
Oblastní nemocnice Kladno a.s.
Kladno, 27259, Czechia
Pro-audio,s.r.o.-private ENT clinic
Mladá Boleslav, 29301, Czechia
ORL oddělení, Všeobecná Fakultní Nemocnice v Praze
Prague, 12808, Czechia
ORL oddělení , Karlovarská krajská nemocnice a. s.
Sokolov, 35601, Czechia
Dr. Ebbo
Issy-les-Moulineaux, 92130, France
Dr. Sarfati
La Seyne-sur-Mer, 83500, France
Centre Hospitalier de Bretagne Sud Service
Lorient, 56322, France
Hopital Edouard Herriot
Lyon, 69437, France
BONFILS
Paris, 75015, France
OHRESSER
Paris, 75015, France
Hopital Nord
Saint-Etienne, 42055, France
FRAYSSE
Toulouse, 31059, France
Service ORL CHU
Tours, 37044, France
Hopital Paul BROUSSE Polyclinique
Villejuif, 94800, France
Andromed Breda
Breda, 4811 VL, Netherlands
Andromed Leiden
Leiderdorp, 2352 RA, Netherlands
Rijnland Ziekenhuis, ENT department
Leiderdorp, 2353 GA, Netherlands
Adromed Nijmegen
Nijmegen, 6533 HL, Netherlands
Andromed Rotterdam
Rotterdam, 3021 HC, Netherlands
Andromed Rotterdam
Rotterdam, HC 3021, Netherlands
Andromed Oost
Velp, 6883 ES, Netherlands
Andromed Zoetermeer
Zoetermeer, 2724 EK, Netherlands
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, 15-279, Poland
Niepubliczny Zaklad Opieki Zdrowotnej Prywatne Centrum Medyczne PROMEDIS
Gdansk, 80-288, Poland
Szpital Miejski im. J.Brudzinskiego
Gdynia, 81-348, Poland
Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, 40-027, Poland
NZOZ Specjalistyczne Centrum Medyczne Nowomed
Krakow, 30-349, Poland
Specjalistyczny Gabinet Otolaryngologiczny Dr Anna Otto- Markiewicz
Krakow, 31-534, Poland
Niepubliczny Zaklad Opieki Zdrowotnej PROMED
Krakow, 31-636, Poland
Szpital Specjalistyczny im. Stefana Zeromskiego, SP ZOZ w Krakowie, Oddzial Otolaryngologii
Krakow, 31-913, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
Lodz, 91-153, Poland
Instytut Medycyny Pracy im. Prof. Dr med. Jerzego Nofera w Lodzi
Lodz, 91-348, Poland
Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszynskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej
Lublin, 20-718, Poland
Wojewodzki Szpital Specjalistyczny w Olsztynie
Olsztyn, 10-561, Poland
Instytut Fizjologii i Patologii Sluchu
Warsaw, 01-943, Poland
Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu
Wroclaw, 50-369, Poland
Louis Leipoldt Mediclinic
Bellville, 7530, South Africa
Lakeview Hospital
Benoni, 1501, South Africa
Dr. A. Viljoen
Pretoria, 0002, South Africa
GCT Eastmed Clinical Trial centre
Pretoria, 0186, South Africa
Constantiaberg Medi Clinic
Western Cape, 7800, South Africa
Dr. J. Steer
Wynberg, 7800, South Africa
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 13, 2008
First Posted
October 15, 2008
Study Start
November 1, 2008
Primary Completion
June 1, 2010
Study Completion
June 1, 2010
Last Updated
July 1, 2010
Record last verified: 2010-06